By targeting keratinocyte differentiation, skin barrier functions, and TSLP expression, SH-340 may offer a multi-faceted approach to the treatment of AD, which could address both the inflammatory and barrier dysfunction aspects of the disease. The gene discussed is TSLP; the disease is Alzheimer disease.